Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia

Donald E. Addington, Somaia Mohamed, Robert A. Rosenheck, Sonia M. Davis, Thomas Scott Stroup, Joseph Patrick McEvoy, Marvin S. Swartz, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004. Method: Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1). Patients with tardive dyskinesia were excluded from the randomization that included perphenazine. Depression was assessed with the Calgary Depression Scale for Schizophrenia (CDSS). Mixed models were used to evaluate group differences during treatment with the initially assigned drug. An interaction analysis evaluated differences in drug response by whether patients had a baseline score on the CDSS of ≥6, indicative of a current major depressive episode (MDE). Results: There were no significant differences between treatment groups on phase 1 analysis, although there was a significant improvement in depression across all treatments. A significant interaction was found between treatment and experiencing an MDE at baseline (P = .05), and further paired comparisons suggested that quetiapine was superior to risperidone among patients who were in an MDE at baseline (P = .0056). Conclusions: We found no differences between any second-generation antipsychotic and the first-generation antipsychotic perphenazine and no support for the clinical practice recommendation, but we did detect a signal indicating a small potential difference favoring quetiapine over risperidone only in patients with an MDE at baseline. Trial Registration: clinicaltrials.gov Identifier: NCT00014001.

Original languageEnglish (US)
Pages (from-to)75-80
Number of pages6
JournalJournal of Clinical Psychiatry
Volume72
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Perphenazine
Antipsychotic Agents
Schizophrenia
Depression
Risperidone
olanzapine
Therapeutics
Pharmaceutical Preparations
Matched-Pair Analysis
Random Allocation
Practice Guidelines
Diagnostic and Statistical Manual of Mental Disorders
Clinical Trials
Quetiapine Fumarate

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. / Addington, Donald E.; Mohamed, Somaia; Rosenheck, Robert A.; Davis, Sonia M.; Stroup, Thomas Scott; McEvoy, Joseph Patrick; Swartz, Marvin S.; Lieberman, Jeffrey A.

In: Journal of Clinical Psychiatry, Vol. 72, No. 1, 01.01.2011, p. 75-80.

Research output: Contribution to journalArticle

Addington, Donald E. ; Mohamed, Somaia ; Rosenheck, Robert A. ; Davis, Sonia M. ; Stroup, Thomas Scott ; McEvoy, Joseph Patrick ; Swartz, Marvin S. ; Lieberman, Jeffrey A. / Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. In: Journal of Clinical Psychiatry. 2011 ; Vol. 72, No. 1. pp. 75-80.
@article{7ee63d8a12ef4b4d955f3601fcaca277,
title = "Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia",
abstract = "Background: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004. Method: Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1). Patients with tardive dyskinesia were excluded from the randomization that included perphenazine. Depression was assessed with the Calgary Depression Scale for Schizophrenia (CDSS). Mixed models were used to evaluate group differences during treatment with the initially assigned drug. An interaction analysis evaluated differences in drug response by whether patients had a baseline score on the CDSS of ≥6, indicative of a current major depressive episode (MDE). Results: There were no significant differences between treatment groups on phase 1 analysis, although there was a significant improvement in depression across all treatments. A significant interaction was found between treatment and experiencing an MDE at baseline (P = .05), and further paired comparisons suggested that quetiapine was superior to risperidone among patients who were in an MDE at baseline (P = .0056). Conclusions: We found no differences between any second-generation antipsychotic and the first-generation antipsychotic perphenazine and no support for the clinical practice recommendation, but we did detect a signal indicating a small potential difference favoring quetiapine over risperidone only in patients with an MDE at baseline. Trial Registration: clinicaltrials.gov Identifier: NCT00014001.",
author = "Addington, {Donald E.} and Somaia Mohamed and Rosenheck, {Robert A.} and Davis, {Sonia M.} and Stroup, {Thomas Scott} and McEvoy, {Joseph Patrick} and Swartz, {Marvin S.} and Lieberman, {Jeffrey A.}",
year = "2011",
month = "1",
day = "1",
doi = "10.4088/JCP.09m05258gre",
language = "English (US)",
volume = "72",
pages = "75--80",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "1",

}

TY - JOUR

T1 - Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia

AU - Addington, Donald E.

AU - Mohamed, Somaia

AU - Rosenheck, Robert A.

AU - Davis, Sonia M.

AU - Stroup, Thomas Scott

AU - McEvoy, Joseph Patrick

AU - Swartz, Marvin S.

AU - Lieberman, Jeffrey A.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004. Method: Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1). Patients with tardive dyskinesia were excluded from the randomization that included perphenazine. Depression was assessed with the Calgary Depression Scale for Schizophrenia (CDSS). Mixed models were used to evaluate group differences during treatment with the initially assigned drug. An interaction analysis evaluated differences in drug response by whether patients had a baseline score on the CDSS of ≥6, indicative of a current major depressive episode (MDE). Results: There were no significant differences between treatment groups on phase 1 analysis, although there was a significant improvement in depression across all treatments. A significant interaction was found between treatment and experiencing an MDE at baseline (P = .05), and further paired comparisons suggested that quetiapine was superior to risperidone among patients who were in an MDE at baseline (P = .0056). Conclusions: We found no differences between any second-generation antipsychotic and the first-generation antipsychotic perphenazine and no support for the clinical practice recommendation, but we did detect a signal indicating a small potential difference favoring quetiapine over risperidone only in patients with an MDE at baseline. Trial Registration: clinicaltrials.gov Identifier: NCT00014001.

AB - Background: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004. Method: Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1). Patients with tardive dyskinesia were excluded from the randomization that included perphenazine. Depression was assessed with the Calgary Depression Scale for Schizophrenia (CDSS). Mixed models were used to evaluate group differences during treatment with the initially assigned drug. An interaction analysis evaluated differences in drug response by whether patients had a baseline score on the CDSS of ≥6, indicative of a current major depressive episode (MDE). Results: There were no significant differences between treatment groups on phase 1 analysis, although there was a significant improvement in depression across all treatments. A significant interaction was found between treatment and experiencing an MDE at baseline (P = .05), and further paired comparisons suggested that quetiapine was superior to risperidone among patients who were in an MDE at baseline (P = .0056). Conclusions: We found no differences between any second-generation antipsychotic and the first-generation antipsychotic perphenazine and no support for the clinical practice recommendation, but we did detect a signal indicating a small potential difference favoring quetiapine over risperidone only in patients with an MDE at baseline. Trial Registration: clinicaltrials.gov Identifier: NCT00014001.

UR - http://www.scopus.com/inward/record.url?scp=79551531085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551531085&partnerID=8YFLogxK

U2 - 10.4088/JCP.09m05258gre

DO - 10.4088/JCP.09m05258gre

M3 - Article

VL - 72

SP - 75

EP - 80

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 1

ER -